Skovronsky Daniel 4

What Happened
Daniel Skovronsky, Executive Vice President, Chief Scientific & Product Officer and President of Lilly Research Laboratories at Eli Lilly (LLY), received a stock award of 15,547.862 shares on February 9, 2026. The award was reported at a per-share value of $1,044.67, for a total grant value of approximately $16,242,385. This transaction is an award/grant (Form 4 code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-09; reported on Form 4 filed 2026-02-11 (appears to be within the typical 2-business-day reporting window).
• Security: Common stock reported as an award/grant (code A).
• Shares granted: 15,547.862; per-share value reported: $1,044.67; total reported value ≈ $16,242,385.
• Shares owned after transaction: not disclosed in the filing.
• Footnote: The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest (Footnote F1).
• No indication in the filing that shares were immediately sold or that this was a cashless exercise.

Context
Stock awards are typically part of executive compensation (e.g., restricted stock units or performance grants) and represent an acquisition for reporting purposes; they do not necessarily reflect a personal market purchase or a directional bet. The footnote clarifies the reporting person’s limited claimed beneficial ownership.